Physician profile
Jason E Mireles
NPI 1255386736
$1,099.62
in general payments reported to CMS, 2019-2025
11 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Foot Surgery provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.29 · 2020: $61.92 · 2021: $91.66 · 2022: $311 · 2023: $274 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.14 |
| Education | $116.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $336.99 | 2022-2025 | Affinity, Via Matrix |
| Kerecis Limited | $141.24 | 2020-2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Nevro Corp. | $128.18 | 2022 | |
| Horizon Therapeutics Plc | $117.24 | 2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $99.29 | 2019 | |
| Grt US Holding, INC. | $91.66 | 2021 | |
| Bard Peripheral Vascular, INC. | $46.61 | 2025 | Fluency Endovascular Stent Graft |
| Boston Scientific Corporation | $46.50 | 2022 | |
| Amniox Medical, INC. | $37.50 | 2020 | |
| Convatec INC. | $32.24 | 2023 | |
| Triad Life Sciences INC. | $22.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Mireles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.